©2024 Stanford Medicine
68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
Not Recruiting
Trial ID: NCT03831711
Purpose
This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen
receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.
Official Title
A Pilot Study of 68-Ga-RM2 PET/MRI in the Evaluation of Patients With Estrogen Receptor-Positive Breast Cancer
Stanford Investigator(s)
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
Eligibility
Inclusion Criteria:
- ER+ breast cancer at initial diagnosis prior to surgery or at recurrence (at least one
ER+ lesion based on results of biopsy).
- Able to provide written consent
- Karnofsky performance status of ≥ 50 (or Eastern Cooperative Oncology Group
(ECOG)/World Health Organization (WHO) equivalent)
Exclusion Criteria:
- Less than 18 years-old at the time of radiotracer administration
- Inability to lie still for the entire imaging time
- Inability to complete the needed investigational and standard-of-care imaging
examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
- Any additional medical condition, serious intercurrent illness, or other extenuating
circumstance that, in the opinion of the Investigator, may significantly interfere
with study compliance
- Renal function impairment preventing administration of MRI contrast
- Metallic implants (contraindicated for MRI)
Intervention(s):
drug: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
procedure: Magnetic Resonance Imaging
procedure: Positron Emission Tomography
device: Investigational software and coils in PET/MR scan
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
David Marcellus
650-723-4547